Objective: To explore the mechanism of Huangqi Guizhi Wuwu Decoction in the treatment of oxaliplatin-induced peripheral neuropathy (OIPN) based on network pharmacology and molecular docking. Methods: Traditional Chinese Medicine System Pharmacology (TCMSP), SwissTargetPrediction Database, Therapeutic Target Database (TTD), Traditional Chinese Medicine Information Database (TCMID), and literature review were used to screen the active ingredients and related targets of Astragali Radix, Cinnamomi Ramulus, Paeonia, Zingiber officinale Roscoe, Jujubae Fructus. Target standardization was carried out by UniProt Database. Cytoscape (V3.9.1) software was used to construct the active ingredient-target network. OIPN related genes were retrieved from GeneCards database. The protein interaction network map was constructed using the STRING database. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of genes and genomes (KEGG) pathway enrichment analysis of potential targets were carried out by R language software and Bioconductor database. Finally, the core active ingredient was docked with the core target by molecular docking technology. Results: After screening, a total of 141 active ingredients and 196 drug targets of Huangqi Guizhi Wuwu Decoction were obtained. The core targets were TNF, IL6, IL1 B, AKT1, CXCL12, etc.; A total of 233 related biological processes were obtained by GO analysis, and 112 signaling pathways were obtained by KEGG analysis. Molecular docking results showed that the core components had good binding energy with the core targets. Conclusion: Huangqi Guizhi Wuwu Decoction in the treatment of OIPN is the result of multi-component, multi-target and multi-pathway interaction, which provides certain theoretical basis for the clinical application and clinical research on OIPN related diseases.
CHENG Jie
,
TANG Yuchen
,
QIN Ruili
,
Dong Zhiqiang
. The mechanism of Huangqi Guizhi Wuwu Decoction in the treatment of oxaliplatin-induced peripheral neuropathy based on network pharmacology[J]. Journal of Baotou Medical College, 2025
, 41(2)
: 82
-87
.
DOI: 10.16833/j.cnki.jbmc.2025.02.015
[1] Cavaletti G, Marmiroli P. Management of oxaliplatin-induced peripheral sensory neuropathy[J]. Cancers, 2020, 12(6): 1370.
[2] 张学兰, 张侠. 奥沙利铂致周围神经病变及其防治研究进展[J]. 药物不良反应杂志, 2016, 18(2): 132-136.
[3] Burgess J, Ferdousi M, Gosal D, et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment[J]. Oncol Ther, 2021, 9(2): 385-450.
[4] 马秋云, 王正田, 马崇, 等. 黄芪桂枝五物汤联合悬吊训练治疗不完全性脊髓损伤患者的康复效果分析[J]. 中国现代医学杂志, 2022, 32(18): 39-44.
[5] 孙鹏, 陈骏, 冯仲珉, 等. 黄芪桂枝五物汤熏洗用于化疗后周围神经毒性的临床分析[J]. 辽宁中医杂志, 2020, 47(5): 141-143.
[6] 张岩, 龙泓竹, 王曦鹏, 等. 黄芪桂枝五物汤加减对糖尿病大鼠坐骨神经内质网应激IRE1α/chop通路的影响[J]. 中国实验方剂学杂志, 2023, 29(16): 43-51.
[7] 陈晨, 马海龙, 顾银霞, 等. 加味黄芪桂枝五物汤治疗奥沙利铂慢性外周神经毒性的临床效果[J]. 中国医药导报, 2023, 20(10): 122-125.
[8] 韩庆亮. 基于网络药理学和体外实验分析莪术醇抗胶质瘤的作用机制[J]. 包头医学院学报, 2023, 39(11): 6-13.
[9] Yang Y, Zhao B, Gao X, et al. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development[J]. J Exp Clin Cancer Res, 2021, 40(1): 331.
[10] 中国抗癌协会肿瘤支持治疗专业委员会. 化疗诱导的周围神经病变诊治中国专家共识(2022版)[J]. 中华肿瘤杂志, 2022, 44(9): 928-933.
[11] 魏国利, 顾展丞, 李灵常, 等. 黄芪桂枝五物汤减少铂蓄积预防奥沙利铂慢性外周神经毒性机制研究[J]. 世界科学技术-中医药现代化, 2019, 21(7): 1467-1473.
[12] Pang B, Zhao Y, Zhao H, et al. Huangqi guizhi wuwu decoction for treating diabetic peripheral neuropathy: a meta-analysis of 16 randomized controlled trials[J]. Neural Regen Res, 2016, 11(8): 1347-1358.
[13] Lotfi N, Yousefi Z, Golabi M, et al. The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: an update[J]. Front Immunol , 2023, 14: 1077531.
[14] Zhang XW, Chen JY, Ouyang D, et al. Quercetin in animal models of alzheimer′s disease: a systematic review of preclinical studies[J]. Int J Mol Sci, 2020, 21(2): 493.
[15] Meade JA, Free B, Miller NR, et al. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling[J]. Psychopharmacology, 2015, 232(5): 917-930.
[16] Di Cesare Mannelli L, Pacini A, Micheli L, et al. Glial role in oxaliplatin-induced neuropathic pain[J]. Exp Neurol, 2014, 261: 22-33.
[17] Was H, Borkowska A, Bagues A, et al. Mechanisms of chemotherapy-induced neurotoxicity[J]. Front Pharmacol, 2022, 13: 750507.
[18] Park HJ, Stokes JA, Corr M, et al. Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice[J]. Cancer Chemother Pharmacol, 2014, 73(1): 25-34.
[19] Jin X, Gereau RW. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha[J]. J Neurosci, 2006, 26(1): 246-255.
[20] Makker PGS, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy[J]. PloS One, 2017, 12(1): e0170814.
[21] Wang YS, Li YY, Cui W, et al. Melatonin attenuates pain hypersensitivity and decreases astrocyte-mediated spinal neuroinflammation in a rat model of oxaliplatin-induced pain[J]. Inflammation, 2017, 40(6): 2052-2061.
[22] Illias AM, Gist AC, Zhang H, et al. Chemokine ccl2 and its receptor ccr2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity[J]. Pain, 2018, 159(7): 1308-1316.
[23] Guo X, Jiang C, Chen Z, et al. Regulation of the jak/stat signaling pathway in spinal cord injury: an updated review[J]. Front Immunol, 2023, 14: 1276445.
[24] Dominguez E, Rivat C, Pommier B, et al. JAK/stat3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat[J]. J Neurochem, 2008, 107(1): 50-60.
